To the Editor:
Winkler and colleagues 1 have published an epidemiological study on the platelet-activating factor acetylhydrolase (PAF-AH) and coronary artery disease. The authors stated erroneously in the Introduction that PAF-AH releases arachidonic acid, a precursor of eicosanoid production including prostaglandins and leukotrienes. On the basis of this assumption, the authors suggest in the Discussion that PAF-AH possesses proinflammatory functions within the atherosclerotic plaque because it is preferentially associated with small dense LDL 2 ; the latter may thus contribute to atherogenesis by functioning as a reservoir of the essential substrate (ie, the arachidonate-containing phosphatidylcholine), and the source of crucial enzyme activity necessary for prostaglandin synthesis. In addition, the authors emphasize that this concept would confer an active role on PAF-AH in atherogenesis rather than it being a mere risk marker.
Actually, PAF-AH, in contrast to other classical phospholipases A 2 that are interfacial enzymes, does not cleave the sn-2 long-chain fatty acids such as arachidonic acid, which contains as many as 20 carbons. PAF-AH acts on its substrates in the aqueous phase, and for this reason it degrades essentially water-soluble phospholipids 3 including PAF, in this case by hydrolyzing its acetate moiety (2 carbons) in the sn-2 position of glycerol. 4 PAF-AH also degrades the short-chain sn-2-analogues of phosphatidylcholine up to 5 carbons 5 or medium-length oxidized chains up to 9 carbons. 3 These molecules are nonenzymatically generated on oxidation of phosphatidylcholine containing an sn-2 polyunsaturated fatty acyl. Of importance, the polyunsaturated fatty acyl is directly truncated into the shortchain oxidized moieties, among which the 1-pamitoyl-2-oxovaleroyl-sn-glycero-3-phosphocholine (POVPC; 5 carbons) is one of the major compounds of minimally modified LDL and atherosclerotic lesions 6 and is an equally good substrate for PAF-AH. 7 For these reasons, PAF-AH was proposed as being a protective mechanism against the accumulation of biologically active oxidized phospholipids in the sites of inflammation, and its exact role in atherogenesis is still under evaluation. 
Response
We thank Dr Nino for commenting on the role of plateletactivating factor acetylhydrolase (PAF-AH) in coronary artery disease (CAD). As outlined by the author, PAF-AH does not act by an interfacial mechanism. The active site of PAF-AH is located toward the aqueous phase and specificity is merely a function of substrate solubility in an aqueous environment. 1 Hence, PAF-AH shows preference to short-chain "hydrophilic" fatty acids, and one important function of PAF-AH is to degrade PAF and proinflammatory oxidized phospholipids. Epidemiological evidence is overwhelming, however, that PAF-AH is clinically associated with increased CAD risk. 2, 3 According to our preliminary data, the risk conferred by PAF-AH appears to be alleviated by the use of aspirin, which would be compatible with an active role of PAF-AH in atherogenesis delivering substrate to the cyclooxygenase (COX) pathway.
We can only speculate about possible mechanisms turning the antiatherogenic function of PAF-AH in plasma into a proatherogenic within the atheromateous plaque. The plaque provides a hydrophobic environment and may not adequately be described by the terms "aqueous" or "nonaqueous." It cannot completely be ruled out that within the hydrophobic environment of the plaque PAF-AH may hydrolyze even long-chain phospholipids. Furthermore, an indirect contribution of PAF-AH to atherogenesis also appears conceivable. Proinflammatory activity may be mediated by the release of products that have a proatherogenic (signaling) function itself. In general, we completely agree with Dr Nino that PAF-AH may possess a dual pro-and antiatherogenic role, depending on the concentration and availability of substrates. 4 We expect future data to elucidate the mechanisms by which
